RANBAXY LABORATORIES LTD. - Ranbaxy Laboratories Ltd reply to clarification sought by the exchange

The Exchange had sought clarification with respect to the following statement of Ranbaxy Laboratories Ltd on December 8, 2014 :<BR><BR>"On December 5, 2014, a jury sitting in the United States District Court for the District of Massachusetts issued a verdict in the esomeprazole antitrust litigation in favor of the defendants AstraZeneca and Ranbaxy. This multidistrict litigation was commenced in 2012. As pertains to Ranbaxy, the lawsuits alleged that Ranbaxy's April 2008 patent settlement agreement with AstraZeneca concerning esomeprazole magnesium violated U.S. antitrust laws.<BR><BR>Ranbaxy is pleased with this verdict, and is committed to serving patients, prescribers and the US healthcare system."<BR><BR>Ranbaxy Laboratories Ltd has vide its emails dated December 8, 2014 and December 11, 2014 respectively clarified that:<BR><BR>1. "Company had issued a Press Release on April 15, 2008 titled "Ranbaxy and Astrazeneca reach Agreement in Esomeprazole Patent Litigation" and details of the Settlement as agreed at that time were disclosed through this Press Release to Stock Exchanges."<BR><BR>2. "Company has not paid any compensation / penalty in the matter."